Big News from Genesys Capital!
We’re thrilled to unveil our brand new logo and revamped website! 🎉
Check out the new site here: genesyscapital.com
4
143
Team Genesys is heading for the 25th time to the #JPM25. The weather forecast looks better than the last year's & we hope that this lifts sentiments across the life sci sector
Also, Genesys originated company @ProfoundMedical will be presenting for the 1st time at JPM this year.
3
434
Congrats to @ProfoundMedical on joining forces with @SiemensHealth under a co-sale and co-marketing agreement! Will be exciting to watch how this partnership + attractive reimbursement drives sales in 2025 #TULSA #prostatecancer #BPH
globenewswire.com/news-relea…
1
121
Toronto host Taylor’s ERAS tour, we're posting our ERAS poster
REPUTATION ERA reflects top-decile DPI w/ exits of Fusion Pharma & Inversago (US$3.5B), & we’re still not done yet – stay tuned for Flosonics/Questat/Veralox
Embarking on our EVERMORE ERA - get your tix today🍁
What an achievement for @ProfoundMedical! “TULSA to stand above all other covered prostate disease treatment modalities at Urology Level 7 reimbursement" - which speaks to the value of the TULSA system. Congrats to the Profound team!
globenewswire.com/news-relea…
Novo announces Monlunabant (Inversago’s INV-202) Phase 2a data in obesity, with significant weight loss after 16 weeks of treatment (7.1 kg with a once daily 10 mg dose).
Based on the results, Novo expects to initiate a larger Phase 2b trial in 2025
novonordisk.com/content/nnco…
2
186
Genesys is closing out a fantastic week at this year’s @MorganStanley Healthcare Conference in NYC.
A highlight for us was hearing @novonordisk's excitement about Monlunabant, acquired from @inversago last year, and its potential to change the landscape of metabolic disease!
With Genesys’ funding, Feldan aims to develop a first-in-class non-invasive intralesional treatment for basal cell carcinoma. We are very excited to be part of Feldan’s “drug delivery platform” mission and it’s an excellent addition to our newest Fund.
newswire.ca/news-releases/fe…
Last month, Fusion Pharmaceuticals exited to AstraZeneca for $2.4 Billion USD - a Genesys co-creation that has become a Canadian anchor company and global hub of radiopharma excellence. Check out the origin story below.
linkedin.com/feed/update/urn…
3
159
Big News for @ProfoundMedical! The CMS has proposed Category 1 CPT codes for TULSA, putting its reimbursement in the same ballpark as standard of care radical prostatectomy, but with better safety outcomes. @RaymondJames rates as a Strong Buy.
globenewswire.com/news-relea…
2
133
TWO Genesys co-creations make the list of Fierce's "Top 10 smartest deals in biopharma" - @inversago & @FusionPharmaInc! A tribute to the value of the Genesys investment thesis #madeinCanada
fiercebiotech.com/biotech/sm…
3
103
Congrats to our very own Damian Lamb for being recognized with a 2024 Alumnus Award from McMaster University! Damian has been committed to supporting the commercialization of McMaster's world-class research for many years #FusionPharma #CPDC
alumni.mcmaster.ca/s/1439/22…
1
114
This week @AstraZeneca completed the acquisition of Genesys portfolio company @FusionPharmaInc for US$2.4B! What a journey it has and we're thrilled to see Ontario becoming a global hub of excellence for radiopharmaceuticals.
prnewswire.com/news-releases…
Congratulations to Genesys Partner and CFO Jennifer Williams on being appointed to the Board of the @cvca ! Proud to have Genesys Capital represented!
Fusion Pharma reveals early Ph2 data from FPI-2265 at #AACR2024
"PSA50 of 50% Exceeds Expectations; Uptake Response and Post-Pluvicto Activity Encouraging; Safety in Line With Previous Data" Andy T. Hsieh, Ph.D. at William Blair
Link to the poster - qrcodes.pro/y32gAO
3
234
Origin Story of Fusion Pharmaceuticals $FUSN
Last week Genesys portfolio company @FusionPharmaInc announced its acquisition by @AstraZeneca! Check out our contributions to this Canadian success story below
No better guest speaker than Genesys' Jamie Stiff for a lecture on "EXITS" - especially as Genesys had US$3.5 Billion in exits since last fall
Kudos to @cvca & @iveybusiness to put together such a good event - CPCIS Program (Canadian Private Capital Investment School)
Good news keeps on flowing here at Genesys: Flosonics secures US$20M Series C to accelerate growth.
Led by @nlvpartners , with participation from previous investors @ArboretumVC, Genesys Capital & @iganvc
Congrats to Joe Eibl & @Flosonics team!
flosonicsmedical.com/flosoni…
BREAKING: Our co-creation exits now totaling US$3.5B in <12 months: $FUSN to be acquired by $AZN for $2.4B
Congrats to John Valliant & @FusionPharmaInc team!
Damian Lamb was the inaugural Chairman of the Board, from company creation through IPO.
ir.fusionpharma.com/2024-03-…
As we await FUSION PHARMA $FUSN to reveal its interim data from the Phase 2 TATCIST Clinical Trial evaluating FPI-2265 at the 2024 AACR in April, RBC did an amazing job in providing RadioPharma landscape
(below image from the recent report titled: Radiopharma on the Rise)














